Class information for: |
Basic class information |
| ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
|---|---|---|---|
| 31066 | 128 | 31.0 | 75% |
Classes in level above (level 2) |
Terms with highest relevance score |
| Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|---|
| 1 | GLICLAZIDE | Author keyword | 4 | 11% | 25% | 32 |
| 2 | INTERNAL MED DIABETOL CLIN PHARMACOL | Address | 2 | 36% | 4% | 5 |
| 3 | DRUG QUAL CONTROL PHARMACOVIGILANC | Address | 1 | 50% | 1% | 1 |
| 4 | GLIBENCIAMIDE | Author keyword | 1 | 50% | 1% | 1 |
| 5 | HUMAN MICROVESSELS | Author keyword | 1 | 50% | 1% | 1 |
| 6 | NAVY HOSP | Address | 1 | 50% | 1% | 1 |
| 7 | ANNUAL SCREENING | Author keyword | 0 | 33% | 1% | 1 |
| 8 | CAS 21187 98 4 | Author keyword | 0 | 33% | 1% | 1 |
| 9 | ELMELETI EGESZSEGTUDOMANYI INTEZET | Address | 0 | 33% | 1% | 1 |
| 10 | EPIDEMIOL POPULAT HLTH EPIDEMIOL DIABET | Address | 0 | 33% | 1% | 1 |
Web of Science journal categories |
Author Key Words |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
|---|---|---|---|---|---|---|---|
| 1 | GLICLAZIDE | 4 | 11% | 25% | 32 | Search GLICLAZIDE | Search GLICLAZIDE |
| 2 | GLIBENCIAMIDE | 1 | 50% | 1% | 1 | Search GLIBENCIAMIDE | Search GLIBENCIAMIDE |
| 3 | HUMAN MICROVESSELS | 1 | 50% | 1% | 1 | Search HUMAN+MICROVESSELS | Search HUMAN+MICROVESSELS |
| 4 | ANNUAL SCREENING | 0 | 33% | 1% | 1 | Search ANNUAL+SCREENING | Search ANNUAL+SCREENING |
| 5 | CAS 21187 98 4 | 0 | 33% | 1% | 1 | Search CAS+21187+98+4 | Search CAS+21187+98+4 |
| 6 | INTRACELLULAR CA2 ELEVATION | 0 | 33% | 1% | 1 | Search INTRACELLULAR+CA2+ELEVATION | Search INTRACELLULAR+CA2+ELEVATION |
| 7 | ANTI OXIDANT STATUS | 0 | 25% | 1% | 1 | Search ANTI+OXIDANT+STATUS | Search ANTI+OXIDANT+STATUS |
| 8 | ENDOTHELIURN | 0 | 25% | 1% | 1 | Search ENDOTHELIURN | Search ENDOTHELIURN |
| 9 | GLICLAZIDE MODIFIED RELEASE | 0 | 25% | 1% | 1 | Search GLICLAZIDE+MODIFIED+RELEASE | Search GLICLAZIDE+MODIFIED+RELEASE |
| 10 | RETINAL LEUKOSTASIS | 0 | 25% | 1% | 1 | Search RETINAL+LEUKOSTASIS | Search RETINAL+LEUKOSTASIS |
Key Words Plus |
| Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | GLICLAZIDE TREATMENT | 1 | 50% | 1% | 1 |
| 2 | INDUCED PULMONARY VASODILATION | 1 | 50% | 1% | 1 |
| 3 | SECONDARY FAILURE RATE | 1 | 50% | 1% | 1 |
| 4 | GLYCOSYLATED HUMAN HEMOGLOBIN | 1 | 22% | 2% | 2 |
| 5 | GLICLAZIDE MR | 0 | 33% | 1% | 1 |
| 6 | PHOTOGRAPHIC PRINTS | 0 | 33% | 1% | 1 |
| 7 | DIABETES INDUCED ACTIVATION | 0 | 25% | 1% | 1 |
| 8 | GLICLAZIDE MODIFIED RELEASE | 0 | 25% | 1% | 1 |
| 9 | SULFONYLUREA AGENTS | 0 | 25% | 1% | 1 |
| 10 | PANC 1 | 0 | 20% | 1% | 1 |
Journals |
Reviews |
| Title | Publ. year | Cit. | Active references | % act. ref. to same field |
|---|---|---|---|---|
| Treating diabetes today with gliclazide MR: a matter of numbers | 2012 | 8 | 45 | 29% |
| Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects | 2003 | 21 | 36 | 25% |
| Hypoglycemic pharmacological treatment of type 2 diabetes: Targeting the endothelium | 2009 | 20 | 221 | 6% |
| Protective actions of gliclazide on high insulin-enhanced neutrophil-endothelial cell interactions through inhibition of mitogen activated protein kinase and protein kinase C pathways | 2004 | 3 | 34 | 29% |
| Effects of oral hypoglycemic agents on platelet function | 2015 | 0 | 72 | 14% |
Address terms |
| Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
|---|---|---|---|---|---|
| 1 | INTERNAL MED DIABETOL CLIN PHARMACOL | 2 | 36% | 3.9% | 5 |
| 2 | DRUG QUAL CONTROL PHARMACOVIGILANC | 1 | 50% | 0.8% | 1 |
| 3 | NAVY HOSP | 1 | 50% | 0.8% | 1 |
| 4 | ELMELETI EGESZSEGTUDOMANYI INTEZET | 0 | 33% | 0.8% | 1 |
| 5 | EPIDEMIOL POPULAT HLTH EPIDEMIOL DIABET | 0 | 33% | 0.8% | 1 |
| 6 | EVANS CLIN MED | 0 | 33% | 0.8% | 1 |
| 7 | IICU | 0 | 33% | 0.8% | 1 |
| 8 | TREATING HOSP | 0 | 33% | 0.8% | 1 |
| 9 | NTT E J AN | 0 | 25% | 0.8% | 1 |
| 10 | DIPARTIMENTO FARMACOL G SEGRE | 0 | 14% | 0.8% | 1 |
Related classes at same level (level 1) |
| Rank | Relatedness score | Related classes |
|---|---|---|
| 1 | 0.0000235959 | GLIMEPIRIDE//JTT 608//SECONDARY FAILURE |
| 2 | 0.0000196847 | ADVANCED OXIDATION PROTEIN PRODUCTS//ADVANCED OXIDATION PROTEIN PRODUCTS AOPP//AOPP |
| 3 | 0.0000177772 | 4150 CLEMENT ST//MED COLUMBIA//AEROBIC WORK CAPACITY |
| 4 | 0.0000126933 | DIABETOL DDG//JOHN COOK RENAL UNIT//PLATELET HYPERSENSITIVITY |
| 5 | 0.0000112931 | PHYSIOL MORPHOL//RAT AORTAE//CHARLIE NORWOOD VET ADM MED |
| 6 | 0.0000105447 | NATEGLINIDE//KAD 1229//REPAGLINIDE |
| 7 | 0.0000102273 | E SELECTIN//ROYAL CITY DUBLIN HOSP EDUC//E SELECTIN GENE |
| 8 | 0.0000094461 | METFORMIN HYDROCHLORIDE//PIOGLITAZONE HYDROCHLORIDE//ROSIGLITAZONE MALEATE |
| 9 | 0.0000091197 | PIOGLITAZONE//ROSIGLITAZONE//THIAZOLIDINEDIONES |
| 10 | 0.0000084903 | SULOFENUR//LY295501//ARYLSULFONYLIMIDAZOLIDINONE |